Imagion Biosystems December 2017 Quarterly Update
In accord with ASX requirements, Imagion Biosystems’ 2017 quarterly update was lodged with the Australian Securities Exchange on 31 January 2018. The update includes Appendix
In accord with ASX requirements, Imagion Biosystems’ 2017 quarterly update was lodged with the Australian Securities Exchange on 31 January 2018. The update includes Appendix
The audio file of the December 2017 Investor Update call is now available. Listen here: Visitors wishing to follow along with the visuals can watch
Imagion Biosystems has updated investors by lodging the latest version of its corporate presentation visuals with the Australian Securities Exchange. Content includes overviews of MagSense®
Imagion Biosystems Limited (Imagion, ASX:IBX) has entered into a Master Service Agreement with ChemConnection BV, a Dutch contract manufacturing organization (CMO) to produce and supply
“Specific Detection of HER-2 positive tumors in mice using superparamagnetic relaxometry” is the title of a poster presented by Erika Vreeland, PhD, at the 2017
This video (below) captures the opening minutes of CEO Bob Proulx’s address to the 2016 NobleCon meeting, where he outlines the medical need for a
Imagion Biosystems Limited (Imagion, ASX:IBX) has entered into a Service Agreement with StarFish Medical (“StarFish”), Canada’s largest medical device design, development and contract manufacturing company,
In accord with ASX requirements, Imagion Biosystems’ quarterly financial statement Appendix 4C was lodged with the Australian Securities Exchange on 31 July, 2017, accompanied by
The 2017 International Convention of BIO, the Biotechnology Innovation Organization, was held June 19-22 in San Diego. More than 16,000 individuals attended BIO 2017, including
Imagion Biosystems President and CEO Bob Proulx was interviewed today by Health Professional Radio, a media network dedicated to promoting awareness on healthcare issues. In
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance